Business Context and Reporting Period
This Form 8-K was filed by OvaScience, Inc. on December 18, 2013. The report details the entry into a material definitive agreement and the formation of a joint venture with Intrexon Corporation to accelerate the development of OvaScience's OvaTure technology platform and pursue new product development in genetic disease prevention and animal health.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines specific financial terms of the new agreements:
- Equity Issuance: OvaScience issued 273,224 shares of common stock to Intrexon upon execution of the collaboration agreement.
- Cash Obligations: OvaScience is obligated to pay a technology access fee of $2.5 million in cash one year after the agreement's execution.
- Joint Venture Capitalization: OvaScience and Intrexon each contributed $1.5 million to the new joint venture, OvaXon, LLC, resulting in a 50% equity interest for each party.
- Royalties: A mid-single digit royalty on net sales of OvaTure products is payable to Intrexon upon delivery of data supporting an Investigational New Drug (IND) application.
Material Changes and Agreements
The primary material change is the establishment of two distinct relationships with Intrexon Corporation:
- OvaTure Collaboration: Intrexon will provide synthetic biology technology to support the filing of an IND for OvaTure. The agreement includes a targeted deadline of two years for technology transfer milestones.
- OvaXon Joint Venture: A new entity, OvaXon, LLC, was formed to combine proprietary technologies. Research and development costs and profits will be split equally (50/50). The venture is governed by a board of managers with equal representation from both companies.
- License Amendment: OvaScience amended its existing license agreement with MGH to clarify that certain human and animal applications fall within the joint venture's field of use.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreements are designed to accelerate the development of OvaTure and expand into genetic disease prevention and animal health. Success is contingent upon Intrexon delivering laboratory and animal data necessary for an IND filing.
Risks and Contingencies:
- Termination Rights: OvaScience may terminate the OvaTure Collaboration with 90 days' prior written notice. Either party may terminate for material breach if not cured within 60 days.
- Unregistered Securities: The 273,224 shares issued to Intrexon were not registered under the Securities Act of 1933 and rely on a Section 4(a)(2) exemption. They are subject to "piggy-back" registration rights for future underwritten public offerings.
- Future Payments: A commercial milestone payment is due three months after the first commercial sale of OvaTure, contingent on product success.
Investor Verification Checklist
- Verify the exact royalty percentage (described only as "mid-single digit") and the specific conditions triggering the payment.
- Confirm the status of the $2.5 million cash payment due one year post-execution and its impact on liquidity.
- Review the amended license agreement with MGH to understand the scope of the clarified human and animal applications.
- Monitor the progress of the two-year technology transfer deadline for the OvaTure IND filing.
- Check for any future registration statements that may include the 273,224 shares issued to Intrexon.